Japer Therapeutics, Inc. Warrants (JSPRW) Financials
Newest figures come from the 10-Q for Q2 FY2026, filed Aug 14, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the JSPRW SEC filings page.
This page shows Japer Therapeutics, Inc. Warrants (JSPRW) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Jasper remains a development-stage cash consumer, while shrinking assets and rising liabilities have sharply reduced its balance-sheet flexibility.
From FY2023 to FY2025, research and development spending rose21.9% while operating cash flow moved from-$52.1M to-$77.2M , indicating continued investment has not yet translated into improved cash conversion. Over the same period, assets fell62.3% as liabilities rose92.2% , meaning the company’s financing structure has become more important than its operating scale.
In FY2025, the operating loss was
By FY2025, liabilities represented 88.4% of assets, compared with
Financial Health Signals
Japer Therapeutics, Inc. Warrants does not currently provide enough eligible data for a peer-relative financial health score, so none is published. The signals and metrics below are current.
Japer Therapeutics, Inc. Warrants passes 1 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
Japer Therapeutics, Inc. Warrants reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.
Key Financial Metrics
Earnings & Revenue
Japer Therapeutics, Inc. Warrants's EBITDA was $11.8M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Japer Therapeutics, Inc. Warrants reported a net loss of $2.8M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Japer Therapeutics, Inc. Warrants earned -$0.10 per diluted share (EPS) in Q2 2026. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.
Not reported for Q2 2026.
Cash & Balance Sheet
Japer Therapeutics, Inc. Warrants held $7.3M in cash as of Q2 2026; no long-term debt figure is on record for that period.
Not reported for Q2 2026.
Not reported for Q2 2026.
Margins & Returns
Japer Therapeutics, Inc. Warrants's quarterly ROE was -195.3% in Q2 2026: one quarter's net income over shareholder equity, not annualized. This is down 81.6 percentage points from the same quarter a year earlier. Against the prior quarter it is down 160.8 percentage points.
Not reported for Q2 2026.
Not reported for Q2 2026.
Not reported for Q2 2026.
Capital Allocation
Japer Therapeutics, Inc. Warrants invested $5.1M in research and development in Q2 2026. This represents a decrease of 75.8% from the same quarter a year earlier. Against the prior quarter it is down 11.7%.
Not reported for Q2 2026.
Not reported for Q2 2026.
JSPRW Income Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | $3.6M-77.3% | $3.6M-62.9% | N/A | $9.3M+6.4% | $15.8M | $9.8M | N/A | $8.8M |
| R&D Expenses | $5.1M-75.8% | $5.8M-64.0% | N/A | $14.4M-0.4% | $21.2M+87.6% | $16.2M+56.9% | N/A | $14.5M-2.6% |
| SG&A Expenses | $4.1M-30.7% | $5.1M-9.0% | N/A | $4.8M-12.1% | $5.9M+25.2% | $5.6M+18.2% | N/A | $5.4M+20.4% |
| Operating Income | -$9.2Mn/m | -$11.0Mn/m | N/A | -$19.2Mn/m | -$27.1Mn/m | -$21.8Mn/m | N/A | -$19.9Mn/m |
| EBITDA | $11.8Mn/m | -$10.9Mn/m | N/A | -$18.9Mn/m | -$26.8Mn/m | -$21.5Mn/m | N/A | -$19.4Mn/m |
| Net Income | -$2.8Mn/m | -$1.2Mn/m | N/A | -$18.7Mn/m | -$26.7Mn/m | -$21.2Mn/m | N/A | -$18.6Mn/m |
| EPS (Basic) | -$0.10 | -$0.04 | $0.23 | -$1.13 | -$1.74n/m | -$1.41n/m | -$1.64n/m | -$1.24 |
| EPS (Diluted) | -$0.10 | -$0.04 | $0.23 | -$1.13 | -$1.74n/m | -$1.41n/m | -$1.64n/m | -$1.24 |
| Diluted Shares (Avg) | 29M | 29M | N/A | 17M | 15M+2.3% | 15M+12.7% | N/A | 15M |
Not reported in any period shown, so not listed: Revenue, Gross Profit, Interest Expense, Income Tax.
JSPRW Balance Sheet
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $11.8M-74.6% | $21.2M-63.2% | $35.8M-55.2% | $57.5M-42.2% | $46.5M-59.2% | $57.6M-54.3% | $79.9M-15.8% | $99.4M-10.0% |
| Current Assets | $11.6M-73.1% | $20.3M-61.8% | $34.6M-54.3% | $54.6M-42.4% | $43.0M-60.5% | $53.2M-55.8% | $75.8M-14.8% | $94.8M-9.9% |
| Cash & Equivalents | $7.3M-81.5% | $14.1M-71.0% | $28.7M-59.9% | $50.9M-45.0% | $39.5M-63.0% | $48.8M-58.8% | $71.6M-17.6% | $92.5M-10.9% |
| Short-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0-100.0% |
| Long-Term Investments | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m | $0n/m |
| Total Liabilities | $10.4M-54.8% | $17.8M+15.8% | $31.6M+73.5% | $45.9M+191.7% | $23.0M+68.6% | $15.4M+20.6% | $18.2M+10.8% | $15.7M-3.3% |
| Current Liabilities | $7.8M-61.7% | $9.0M-27.1% | $13.2M-13.4% | $21.0M+68.9% | $20.5M+103.6% | $12.3M+38.3% | $15.2M+23.1% | $12.5M+4.6% |
| Non-Current Liabilities | $2.5M+3.2% | $8.8M+191.1% | $18.4M+516.7% | $24.9M+659.2% | $2.5M-30.6% | $3.0M-20.9% | $3.0M-26.7% | $3.3M-25.0% |
| Total Equity | $1.4M-94.0% | $3.4M-92.0% | $4.2M-93.3% | $11.6M-86.2% | $23.5M-76.6% | $42.2M-62.7% | $61.7M-21.4% | $83.7M-11.1% |
| Retained Earnings | -$320.6Mn/m | -$317.8Mn/m | -$316.7Mn/m | -$307.6Mn/m | -$288.8Mn/m | -$262.1Mn/m | -$240.9Mn/m | -$216.5Mn/m |
Not reported in any period shown, so not listed: Inventory, Accounts Receivable, Goodwill, Long-Term Debt.
JSPRW Cash Flow Statement
Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$6.9Mn/m | -$14.5Mn/m | -$21.9Mn/m | -$17.0Mn/m | -$15.5Mn/m | -$22.8Mn/m | -$21.1Mn/m | -$14.1Mn/m |
| Depreciation & Amortization | $21.0M+6900.0% | $21K-92.5% | $290K+18.4% | $229K-54.2% | $300K0.0% | $279K-3.1% | $245K | $500K+66.7% |
| Stock-Based Compensation | N/A | $423K-76.6% | N/A | $1.4M-28.7% | $1.8M+22.6% | $1.8M+54.9% | N/A | $2.0M+43.2% |
| Investing Cash Flow | N/A | N/A | $0n/m | $0n/m | $1Kn/m | $4Kn/m | -$76Kn/m | -$274Kn/m |
| Financing Cash Flow | N/A | N/A | -$340K-198.6% | $28.4M+315322.2% | N/A | N/A | $345Kn/m | $9K-75.0% |
Not reported in any period shown, so not listed: Capital Expenditures, Free Cash Flow, Dividends Paid, Share Buybacks.
JSPRW Financial Ratios
Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.
| Metric | Q2'2610-Q | Q1'2610-Q | Q4'2510-Q | Q3'2510-Q | Q2'2510-Q | Q1'2510-Q | Q4'2410-K | Q3'2410-Q |
|---|---|---|---|---|---|---|---|---|
| Return on Equity | -195.3%-81.6pp | -34.5%+15.8pp | N/A | -161.9%-139.7pp | -113.7%-99.2pp | -50.3%-38.2pp | N/A | -22.3%-3.6pp |
| Return on Assets | -23.4%+34.1pp | -5.5%+31.3pp | N/A | -32.6%-13.9pp | -57.5%-44.7pp | -36.9%-26.0pp | N/A | -18.8%-2.9pp |
| Current Ratio | 1.48-0.6x | 2.26-2.1x | 2.62-2.4x | 2.59-5.0x | 2.10-8.7x | 4.31-9.2x | 4.98-2.2x | 7.61-1.2x |
| Liabilities-to-Equity | 7.35+6.4x | 5.23+4.9x | 7.62+7.3x | 3.97+3.8x | 0.98+0.8x | 0.36+0.3x | 0.30+0.1x | 0.190.0x |
Not reported in any period shown, so not listed: Gross Margin, Operating Margin, Net Margin, Debt-to-Equity, Asset Turnover, FCF Margin.
Where Japer Therapeutics, Inc. Warrants Ranks
Frequently Asked Questions
Is Japer Therapeutics, Inc. Warrants profitable?
No, Japer Therapeutics, Inc. Warrants (JSPRW) reported a net loss of $76 in fiscal year 2025.
What is Japer Therapeutics, Inc. Warrants's EBITDA?
Japer Therapeutics, Inc. Warrants (JSPRW) had EBITDA of -$82.8M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Japer Therapeutics, Inc. Warrants's return on equity (ROE)?
Japer Therapeutics, Inc. Warrants (JSPRW) has a return on equity of 0.0% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Japer Therapeutics, Inc. Warrants's operating cash flow?
Japer Therapeutics, Inc. Warrants (JSPRW) recorded an outflow of $77.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.
What are Japer Therapeutics, Inc. Warrants's total assets?
Japer Therapeutics, Inc. Warrants (JSPRW) had $35.8M in total assets as of fiscal year 2025, including both current and long-term assets.
How much does Japer Therapeutics, Inc. Warrants spend on research and development?
Japer Therapeutics, Inc. Warrants (JSPRW) invested $63.1M in research and development during fiscal year 2025.
What is Japer Therapeutics, Inc. Warrants's current ratio?
Japer Therapeutics, Inc. Warrants (JSPRW) had a current ratio of 2.62 as of fiscal year 2025, which is generally considered healthy.
What is Japer Therapeutics, Inc. Warrants's liabilities-to-equity ratio?
Japer Therapeutics, Inc. Warrants (JSPRW) had a liabilities-to-equity ratio of 7.62 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity. No debt-to-equity ratio is shown for fiscal year 2025, because the filing data we hold for that year carries no long-term debt figure.
What is Japer Therapeutics, Inc. Warrants's return on assets (ROA)?
Japer Therapeutics, Inc. Warrants (JSPRW) had a return on assets of 0.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
How does Japer Therapeutics, Inc. Warrants's liquidity compare with its operating cash outflow?
At the end of fiscal year 2025, Japer Therapeutics, Inc. Warrants (JSPRW) held $28.7M in cash, cash equivalents and investments, and reported an operating cash outflow of $77.2M over that year. Dividing the one by the other, the reported balance equals about 4 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.
What is Japer Therapeutics, Inc. Warrants's Piotroski F-Score?
Japer Therapeutics, Inc. Warrants (JSPRW) has a Piotroski F-Score of 1 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Japer Therapeutics, Inc. Warrants's earnings high quality?
Japer Therapeutics, Inc. Warrants (JSPRW) reported a net loss of $76 while operations used $77.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.